section name header

Interacting Drugs

OBJECT DRUGS

Phosphodiesterase Inhibitors:

PRECIPITANT DRUGS

Enzyme Inhibitors:


Comment:

The phosphodiesterase inhibitors are metabolized by CYP3A4; concurrent administration with CYP3A4 inhibitors could produce increased plasma concentrations. Increased side effects may occur during coadministration with CYP3A4 inhibitors.


Class 3: Assess Risk & Take Action if Necessary